Express Scripts Statement on Administration's Comments on Drug Pricing
Get Alerts ESRX Hot Sheet
Join SI Premium – FREE
ST. LOUIS, May 11, 2018 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) released the following statement in response to the Administration's announcement today on prescription drug costs:

"President Trump rightly recognizes drug companies charge way too much, and their prices need to come down. Express Scripts leads the way in reining in costs and improving care. By taking on tough challenges, we helped employers save $32 billion on their prescription drug bill in 2017 alone. We take decisive action to improve affordability and access for the 83 million Americans we serve. For more than 30 years, Express Scripts has been a champion in the fight to lower drug costs. Express Scripts stands up to drug companies and drug stores to make sure that everyone – patients, employers, health plans, unions and public programs – get a fair deal for the money they spend. It is clear, based on today's comments, that our role has never been more important to improving healthcare."
"In particular we were pleased that the Administration recognized and endorsed policies that we have advocated for over the years, including increasing access to biosimilars, increasing the number of generic drugs available, and eliminating gag clauses and clawbacks -- anti-patient practices that we do not engage in. We look forward to working with the Administration to enact pro-patient, pro-payer policies."
About Express ScriptsExpress Scripts is leading the way for tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.
Headquartered in St. Louis, Express Scripts provides a full range of integrated pharmacy benefit management services, including home delivery pharmacy care, specialty pharmacy care and benefit management, benefit-design consultation, drug utilization review, formulary management and medical and drug data analysis, that guide patients and plans toward better health by prioritizing care and increasing savings. Our services drive down the cost of care for employer-funded, Medicare, Medicaid and Public Exchange plans, and create the headroom needed to keep patients' cost-share low, access broad, and do more for those who are challenged by high out-of-pocket costs. Express Scripts also distributes a full range of biopharmaceutical products and offers innovative medical benefit management services.
For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.
Media Contact:
Phil Blando202-383-7982[email protected]
View original content with multimedia:http://www.prnewswire.com/news-releases/express-scripts-statement-on-administrations-comments-on-drug-pricing-300647163.html
SOURCE Express Scripts
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Persistent Strengthens Enterprise AI Engineering Talent Pipeline Through Collaboration with Databricks and Milwaukee School of Engineering
- Best Meme Coins to Buy Today? APEMARS Leads 7 Other Coins as Stage 23 Nears Final Breakout Phase
- Realkredit Danmark A/S publishes new Base Prospectus for mortgage covered bonds and mortgage bonds
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share